Bruce Sachs - Vertex Pharmaceuticals Co-Lead Independent Director

VRTX -- USA Stock  

Fiscal Quarter End: December 31, 2019  

Mr. Bruce I. Sachs is Colead Independent Director of Vertex Pharmaceuticals Incorporated. Mr. Sachs is a General Partner at Charles River Ventures, a VC firm he joined in 1999. From 1998 to 1999, he served as Executive Vice President and General Manager of Ascend Communications, Inc. From 1997 until 1998, Mr. Sachs served as President and Chief Executive Officer of Stratus Computer, Inc. From 1995 to 1997, he served as Executive Vice President and General Manager of the Internet Telecom Business Group at Bay Networks, Inc. From 1993 to 1995, he served as President and Chief Executive Officer of Xylogics, Inc
Age: 58  Director Since 2017  MBA    
617 341-6100
Sachs holds a B.S.E.E. in electrical engineering from Bucknell University, an M.E.E. in electrical engineering from Cornell University, and an M.B.A. from Northeastern University.

Bruce Sachs Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.3 % which means that it generated profit of $8.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 51.75 % meaning that it created $51.75 on every $100 dollars invested by stockholders.
The company currently holds 649.8 M in liabilities with Debt to Equity (D/E) ratio of 12.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Geoffrey ParkerPerrigo Company Plc
Bruce CarterDr Reddys Laboratories Ltd
Shlomo YanaiPerrigo Company Plc
Theodore SamuelsPerrigo Company Plc
Sridar IyengarDr Reddys Laboratories Ltd
Yingqi XiaOrigin Agritech Limited
Gary CohenPerrigo Company Plc
Anthony ColesRegeneron Pharmaceuticals
Theodore SamuelstoPerrigo Company Plc
Geoffery MerszeiOrigin Agritech Limited
James KangOrigin Agritech Limited
Allan ObermanDr Reddys Laboratories Ltd
Fei WangOrigin Agritech Limited
Marc TessierLavigneRegeneron Pharmaceuticals
Ellen HoffingPerrigo Company Plc
Donal OConnorPerrigo Company Plc
Jeffrey SmithPerrigo Company Plc
Omkar GoswamiDr Reddys Laboratories Ltd
Anupam PuriDr Reddys Laboratories Ltd
Herman MorrisPerrigo Company Plc
William DoyleZoetis

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Did you try this?

Run Correlation Analysis Now


Correlation Analysis

Reduce portfolio risk simply by holding instruments which are not perfectly correlated
All  Next Launch Module

Also Currentnly Active

Purchased over 70 shares of
few hours ago
Traded for 36.89
Purchased few shares of
few hours ago
Traded for 163.21
Purchased over 70 shares of
few hours ago
Traded for 36.89
Also please take a look at World Market Map. Please also try Pair Correlation module to compare performance and examine historical correlation between any two equity instruments.